Core Laboratories N.V. (NYSE:CLB) has made a 1.4% comeback from a 12-month low price of $78.44. It was seen -6.45% lower, changing the price to $79.54, when the closing bell rang on 12/04/2018. At recent session, the prices were hovering between $79.33 and $85.2287. This company shares are 32.17% off its target price of $105.13 and the current market capitalization stands at $3.51B. The recent change has given its price a -17.53% deficit over SMA 50 and -38.97% deficit over its 52-week high. The stock witnessed -7.54% declines, -28.39% declines and -36.45% declines for the 1-month, 3-month and 6-month period, respectively. To measure price-variation, we found CLB’s volatility during a week at 4.26% and during a month it has been found around 3.63%.Core Laboratories N.V. (CLB) Top Holders
Institutional investors currently hold around $4.34 billion or 0% in CLB stock. Look at its top three institutional owners. Wcm Investment Management/Ca owns $414.05 million in Core Laboratories N.V., which represents roughly 11.8% of the company’s market cap and approximately 9.54% of the institutional ownership. Similar statistics are true for the second largest owner, Clearbridge Investments, Llc, which owns 4,828,901 shares of the stock are valued at $410.55 million. The third largest holder is Vanguard Group Inc, which currently holds $331.19 million worth of this stock and that ownership represents nearly 9.44% of its market capitalization.
At the end of September reporting period, 175 institutional holders increased their position in Core Laboratories N.V. (NYSE:CLB) by some 3,787,662 shares, 173 decreased positions by 3,581,096 and 64 held positions by 43,690,956. That puts total institutional holdings at 51,059,714 shares, according to SEC filings. The stock grabbed 38 new institutional investments totaling 241,682 shares while 49 institutional investors sold out their entire positions totaling 839,165 shares.Core Laboratories N.V. (NYSE:CLB) Insider Trades
Multiple company employees have indulged in significant insider trading. Core Laboratories N.V. disclosed in a document filed with the US Securities and Exchange Commission (SEC) that Director Sodderland Jan Willem has acquired 200 shares of Core Laboratories N.V. (CLB) in trading session dated Oct. 29, 2018. These shares are worth $17,152 and were traded at $85.76 each. The SEC filing shows that Daniels Kevin performed a sale of 73 shares. The CAO & Treasurer disposed these shares by way of transaction on Aug. 14, 2018. The company’s shares were given away at $112.63 per share worth to an income of some $8,222 on account of Daniels Kevin.
Director, Straughen Michael, purchased 106 common shares of Core Laboratories N.V. (CLB) in the open market. In a transaction dated Feb. 01, 2017, the shares were bought at an average price of $118.65, giving away a sum of $12,577. After this purchase, 106 common shares of CLB are directly owned by the insider, with total stake valued at $8,431.
In the transaction dated Jan. 30, 2017, the great number of shares acquired came courtesy the Director; Carnes Martha Z. added a total of 200 shares at an average price of $115.2, amounting to approximately $23,040. The insider now directly owns 200 shares worth $15,908.
Several analysts have released their opinion on Core Laboratories N.V. (NYSE:CLB), with 2 analysts believing it is a strong buy. Whereas 7 of them predict the stock is a hold. Also, there are 5 buy, 0 sell and 1 strong sell ratings, collectively assigning a 2.53 average brokerage recommendation.